IN8bio (INAB) Projected to Post Earnings on Thursday

IN8bio (NASDAQ:INAB) will likely be announcing its earnings results on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

IN8bio Stock Up 3.5 %

IN8bio stock opened at $0.27 on Thursday. The company has a fifty day simple moving average of $0.28 and a 200 day simple moving average of $0.31. IN8bio has a 1-year low of $0.22 and a 1-year high of $1.74. The company has a market cap of $19.43 million, a P/E ratio of -0.36 and a beta of 0.05. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of IN8bio in a research note on Wednesday, February 12th.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.